Brivanib (BRI) versus Sorafenib (SOR) as First-line Therapy in Patients with Unresectable, Advanced Hepatocellular Carcinoma (HCC): Results from the Phase 3 BRISK-FL Study

臺大醫院-腫瘤醫學部;臺大醫學院-內科;Johnson, PhillipPhillipJohnsonQin, ShukuiShukuiQinPark, Joong-WonJoong-WonParkPoon, Ronnie T.Ronnie T.PoonRaoul, Jean-LucJean-LucRaoulPhilip, Philip A.Philip A.PhilipHsu, Chih-HungChih-HungHsuHu, Tsung-HuiTsung-HuiHuHeo, JeongJeongHeoXu, JianmingJianmingXuLu, LigongLigongLuChao, YeeYeeChaoBoucher, EvelineEvelineBoucherHan, Kwang-HyubKwang-HyubHanPaik, Seung WoonSeung WoonPaikRobles-Avina, JorgeJorgeRobles-AvinaKudo, MasatoshiMasatoshiKudoLiu, DavidDavidLiuEzzeddine, RanaRanaEzzeddineWalters, IanIanWaltersCheng, Ann-LiiAnn-LiiCheng2014-02-142018-07-112014-02-142018-07-112012http://ntur.lib.ntu.edu.tw//handle/246246/25982782 bytestext/htmlBrivanib (BRI) versus Sorafenib (SOR) as First-line Therapy in Patients with Unresectable, Advanced Hepatocellular Carcinoma (HCC): Results from the Phase 3 BRISK-FL Studyhttp://ntur.lib.ntu.edu.tw/bitstream/246246/259827/1/index.html